What’s the current market cap for Mesa Laboratories stock?

Mesa Laboratories (MLAB) has a market cap of $574m as of June 07, 2026.

What is the P/E ratio for Mesa Laboratories stock?

The price to earnings (P/E) ratio for Mesa Laboratories (MLAB) stock is 85.86 as of June 07, 2026.

Does Mesa Laboratories stock pay dividends?

Yes, the Mesa Laboratories (MLAB) stock pays dividends to shareholders. As of June 07, 2026, the dividend rate is $0.64 and the yield is 0.62%. Mesa Laboratories has a payout ratio of 52.49% on a trailing twelve-month basis.

When is the next Mesa Laboratories dividend payment date?

The next Mesa Laboratories (MLAB) dividend payment is scheduled for June 15, 2026.

What is the beta indicator for Mesa Laboratories?

Mesa Laboratories (MLAB) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Mesa Laboratories stock | $MLAB Share Price

13:30

15:10

16:45

18:25

20:00

About Mesa Laboratories

Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Ticker

$MLAB

Sector

Health

Primary listing

NASDAQ

Employees

717

Headquarters

Lakewood, United States

Website

www.mesalabs.com

MLAB Metrics

BasicAdvanced

$574m

85.86

$1.21

0.93

$0.64

0.62%

What the Analysts think about MLAB

Analyst ratings (Buy, Hold, Sell) for Mesa Laboratories stock.

Bulls say / Bears say

Mesa Laboratories posted a 5.0% increase in revenues in 2Q26, and operating income rose 34.7% to $4.724 million, showing strong operational leverage.

In 3Q26, total revenues increased 3.6% year-over-year to $65.126 million, operating income jumped 38.0% to $7.975 million, and net income turned positive at $3.63 million from a $1.676 million loss, demonstrating greater profitability.

The company repaid $8.7 million in debt during 3Q26, lowering its total net leverage ratio to 2.62×, which improved its balance sheet and financial flexibility.

The Clinical Genomics division experienced a 7.1% year-over-year drop in revenues in 3Q26 due to regulatory and tariff challenges in China, showing the risks of exposure to key markets.

Calibration Solutions saw organic revenues decline by 2.5% in 3Q26, with a 100 basis point decrease in gross margin, indicating volatility from end-of-year ordering and an unfavorable product mix.

Core organic revenue growth reached only 1.2% in 3Q26, while adverse currency effects reduced results by about 120 basis points, underscoring the company’s vulnerability to exchange rate movements and sluggish underlying demand.

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

MLAB Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

MLAB Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MLAB

Capital at risk

Market closed

Upcoming events

Bulls say / Bears say

Mesa Laboratories posted a 5.0% increase in revenues in 2Q26, and operating income rose 34.7% to $4.724 million, showing strong operational leverage.

The company repaid $8.7 million in debt during 3Q26, lowering its total net leverage ratio to 2.62×, which improved its balance sheet and financial flexibility.

The Clinical Genomics division experienced a 7.1% year-over-year drop in revenues in 3Q26 due to regulatory and tariff challenges in China, showing the risks of exposure to key markets.

Calibration Solutions saw organic revenues decline by 2.5% in 3Q26, with a 100 basis point decrease in gross margin, indicating volatility from end-of-year ordering and an unfavorable product mix.

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

About Mesa Laboratories

Ticker

Employees

MLAB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about MLAB

Analyst Ratings

Bulls say / Bears say

MLAB Financial Performance

Income Statement

MLAB Earnings Performance

Earnings per share (EPS)

Buy $MLAB

Upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Mesa Laboratories/$MLAB

About Mesa Laboratories

Ticker

Employees

MLAB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about MLAB

Analyst Ratings

Bulls say / Bears say

MLAB Financial Performance

Income Statement

MLAB Earnings Performance

Earnings per share (EPS)

Buy $MLAB

Upcoming events

What’s the current market cap for Mesa Laboratories stock?

What is the P/E ratio for Mesa Laboratories stock?

Does Mesa Laboratories stock pay dividends?

When is the next Mesa Laboratories dividend payment date?

What is the beta indicator for Mesa Laboratories?

Bulls say / Bears say